Investor Presentaiton

Globalization - Maximize Product Value Revenue from regions outside Chinese Mainland and other countries 1H22 Revenue RMB $7,592 million European subsidiary established in 2017 based on various collaborations, to capture the value of innovative medicines Launched the first domestic biosimilar in EU Covering early stage incubation, BD, preclinical and clinical research and other innovative R&D Global Presence RMB5, 198 million in 1H21 % Total Revenue Europe United States Past Now & future 11 35.58% 30.66% in 1H21 1H22 Main Progress The U.S. • • Collaborated with 5 major wholesalers, 16 GPOs, 21 distributors in the U.S. market. 19 collaboration contracts covered 85% of the IDNS Sisram's North American direct sales revenue was USD69.9 million (+42.2% YoY), 40% of the total revenue Africa Côte d'Ivoire Pharmaceutical distribution hub in West Africa has been put into operation; Kenya . Africa India Acquired the third largest pharma distributor in French-speaking West Africa, Tridem Pharma, in 2017 Integrated public markter team in Guilin Pharma with private market team inTridem Pharma Established 5 regional distribution hubs with about 800 people in the commercialization team Strengthening marketing and local manufacturing capabilities Figure number: GS(2016)1666 Acquired the first FDA approved injectables manufacturer in India, Gland Pharma, in 2017 Focusing on complex injectables and expanding to biologics CDMO Accelerating product registration in China 6,099 overseas employees, 16.7% of the total number of employees distribution hub passed the ICRC on- Completed the first stage of globalization site inspection Accelerating the overseas commercialization of competitive products Entered into the U.S. market by exporting formulations and other businesses. Established the U.S. subsidiary in 2017. Has Hengenix Biotech, Fusion and other platforms in the U.S. Building the 2nd headquarter in the U.S. to improve operation Have direct sales team for generic drugs and medical devices Strengthening BD capability of clinical stage products and commercialization capability of innovative medicines

View entire presentation